おかえりなさい
アカウント登録
siteでログインする
siteで登録する
受信トレイを確認する
Gen9
About
Gen9 provides gene synthesis technology that enables the high-throughput, automated production of DNA constructs.
- 11 - 50
Highlights
Details
- Last Funding Type
- Private Equity（PE）
- Last Funding Money Raised
- $21M
- Industries
- Biotechnology,Genetics,Manufacturing
- Founded date
- Jan 1, 2009
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Gen9 is building on advances in synthetic biology to power a scalable fabrication capability that will significantly increase the world’s capacity to produce DNA content. The privately held company’s next-generation gene synthesis technology allows for the high-throughput, automated production of DNA constructs at lower cost and higher accuracy than previous methods on the market. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels.Gen9 was established in 2009 and is based in Cambridge, Massachusetts, United States.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 24, 2013 | Private Equity（PE） | $21M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Agilent Technologies
|
— | Private Equity（PE） |
